Inhibition of thrombin: Relevance to anti-thrombosis strategy

Frontiers in Bioscience

Volumn 11, Issue 1 P.1-446, 2006, Pages 113-120

  Shen, Garry X ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Blood; Coagulation; Peptidomimetics; Review; Statins; Thrombin; Thrombin specific inhibitors; Thrombosis

Indexed keywords

HIRUDINIDA;

EID: 32844460078     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1783     Document Type: Review

References (78)

1. Fareed J, B. E. Lewis, D. D. Callas, D. A. Hoppensteadt, J. M. Walenga & R. L. Bick: Antithrombin agents: the new class of anticoagulant and antithrombotic drugs. Clin Appl Thromb Hemost 5, S45-55 (1999)
2. Fenton II JW, F. A. Ofosu, D.V. Brezniak & H.I. Hassouna: Understanding thrombin and hemostasis. Hematol Oncol Clin North Am 7, 1107-1119 (1993)
3. Samama MM, L. Bara & I. Gouin-Thibault: New data on the pharmacology of heparin and low molecular weight heparins. Drugs 52 Suppl 7, 8-14 (1996)
4. Leizorovicz A, M. C. Haugh, F. R. Chapuis, M.M. Samama & J. P. Boissel: Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 305, 913-920 (1992)
5. Amiral J, M. Wolf, A. Fischer, C. Boyer-Neumann, A. Vissac, & D. Meyer: Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 92, 954-959 (1996)
6. Ortel TL: Heparin-induced thrombocytopenia. Semin Hematol 35, 1-2 (1998)
7. Sanderson PE & A. M. Naylor-Olsen: Thrombin inhibitor design. Curr Med Chem 5, 289-304 (1998)
8. Fenton II JW: Leeches to hirulogs and other thrombin-directed antithrombotics. Hematol Oncol Clin North Am 6, 1121-1129 (1992)
9. Rewinkel JB & A. E. Adang: Strategies and progress towards the ideal orally active thrombin inhibitor. Curr Pharm Des 5, 1043-1075 (1999)
10. Kikelj D: Peptidomimetic thrombin inhibitors. Pathophysiol Haemost Thromb 33, 487-491 (2003/2004)
11. Fenton II JW, D.V. Brenzniak, F.A. Ofosu, G.X. Shen, J.R. Jacobson, J.G. Garcia: Thrombin and thrombosis. Cur Drug Target: Cardiovasc Haematol Disord 5, 115-120 (2005)
12. Fields WS: The history of leeching and hirudin. Haemostasis 21 Suppl 1, 3-10 (1991)
13. Markwardt F: Hirudin and derivatives as anticoagulant agents. Thromb Haemost 66, 141-152 (1991)
14. Braun PJ, S. Dennis, J. Hofsteenge, & S. R. Stone: Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry 27, 6517-6522 (1988)
15. Eriksson BI, P. Wille-Jorgensen, P. Kalebo, P. Mouret, N. Rosencher, P. Bosch, M. Baur, S. Ekman, D. Bach, S. Lindbratt & P. Close: A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 337, 1329-1335 (1997)
16. Eriksson BI, S. Ekman, S. Lindbratt, M. Baur, D. Bach, C. Torholm, P. Kalebo & P. Close: Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 79, 326-333 (1997)
17. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Circulation 90, 1631-1637 (1994)
18. Antman EM: Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 90, 1624-1630 (1994)
19. Neuhaus KL, R. von Essen, U. Tebbe, A. Jessel, H. Heinrichs, W. Maurer, W. Doring, D. Harmjanz, V. Kotter, E. Kalhammer & et al: Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK) Circulation 90: 1638-1642 (1994)
20. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 335, 775-782 (1996)
21. Antman EM: Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 94, 911-921 (1996)
22. Rade JJ, A. H. Schulick, R. Virmani & D.A. Dichek: Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med 2, 293-298 (1996)
23. Serruys PW, J. P. Herrman, R. Simon, W. Rutsch, C. Bode, G. J. Laarman, R. van Dijk, A. A. van den Bos, V. A. Umans, K. A. Fox & et al: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 333, 757-763 (1995)
24. Gallo R, A. Padurean, V. Toschi, J. Bichler, J.T. Fallon, J. H. Chesebro, V. Fuster & J. J. Badimon: Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. Circulation 97, 581-588 (1998)
25. Witting JI, D.V. Brezniak, J. R. Hayes & J.W. Fenton II: Human alpha- and zeta-thrombin inhibition by recombinant HV1 and HV2K47 hirudins. Thromb Res 63, 473-479 (1991)
26. Fenton II JW, J. I. Witting, C. Pouliott & J. Fareed: Thrombin anion-binding exosite interactions with heparin and various polyanions. Ann N Y Acad Sci 556, 158-165 (1989)
27. Maraganore JM, P. Bourdon, J. Jablonski, K. L. Ramachandran & J. W. Fenton II: Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29, 7095-7101 (1990)
28. Witting JI, P. Bourdon, J. M. Maraganore & J. W. Fenton II. Hirulog-1 and -B2 thrombin specificity. Biochem J 287, 663-664 (1992)
29. Lidon RM, P. Theroux, M. Juneau, B. Adelman & J. Maraganore: Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects. Circulation 88, 1495-1501 (1993)
30. Lidon RM, P. Theroux, J. Lesperance, B. Adelman, R. Bonan, D. Duval & J. Levesque: A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction, Circulation 89, 1567-1572 (1994)
31. Bittl JA & F. Feit: A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators. Am J Cardiol 82, 43P-49P (1998)
32. French JK & H. D. White: Antithrombin agents as adjuncts to thrombolytic therapy. J Thromb Thrombolysis 8, 159-166 (1999)
33. Topol EJ: Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET) Am J Cardiol 82, 63P-68P (1998)
34. Hamelink JK, D. B. Tang, C. F. Barr, M. R. Jackson, T. J. Reid, E. R. Gomez & B. M. Alving: Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model. J Vasc Surg 21, 492-498 (1995)
35. Ren S, J. W. Fenton II, J. M. Maraganore, A. Angel & G. X. Shen: Inhibition by hirulog-1 of generation of plasminogen activator inhibitor-1 from vascular smooth-muscle cells induced by thrombin, J Cardiovasc Pharmacol 29, 337-342 (1997)
36. Xue M, J. W. Fenton II & G. X. Shen: Hirulog-1 reduces expression of platelet-derived growth factor in neointima of rat carotid artery induced by balloon catheter injury. J Vasc Res 37, 82-92 (2000)
37. Sarembock IJ, S. D. Gertz, L. M. Thome, K. W. McCoy, M. Ragosta, E. R. Powers, J. M. Maraganore & L. W. Gimple: Effectiveness of hirulog in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. J Vasc Res 33, 308-314 (1996)
38. Steinmetzer T, M. Batdordshjin, F. Pineda, L. Seyfarth, A. Vogel, S. Reissmann, J. Hauptmann & J. Sturzebecher: New bivalent thrombin inhibitors with N(alpha)(methyl)arginine at the P1-position. Biol Chem 381, 603-610 (2000)
39. Krishnan R, A. Tulinsky, G. P. Vlasuk, D. Pearson, P. Vallar, P., Bergum, T. K. Brunck & W. C. Ripka: Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an alpha-ketc-amide transition-state mimetic. Protein Sci 5, 422-433 (1996)
40. Deschenes I, C. D. Finkle & P. D. Winocour: Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model. Thromb Haemost 80, 186-191 (1998)
41. Shen GX: Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders. Int J Mol Med 1, 399-408 (1998)
42. Chen X, S. Ren, M.G. Ma, S. Dharmalingam, L. Lu, M. Xue, J. Ducas & G.X. Shen. Hirulog-like peptide reduces restenosis and expression of tissue factor and transforming growth factor-beta in carotid artery of atherosclerotic rabbits. Atherosclerosis 169, 31-40 (2003)
43. Okamoto S, A. Hijikata, R. Kikumoto, S. Tonomura, H. Hara, K. Ninomiya, A. Maruyama, M. Sugano & Y. Tamao: Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 101, 440-446 (1981)
44. Kawada T, H. Kitagawa, M. Hoson, Y. Okada & J. Shiomura: Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation, Hematol Oncol Clin North Am 14, 445-457 (2000)
45. Fareed J & W.P. Jeske: Small-molecule direct antithrombins: argatroban. Best Pract Res Clin Haematol 17, 127-138 (2004)
46. Callas DD, D. Hoppensteadt & J. Fareed: Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin. Semin Thromb Hemost 21, 177-183 (1995)
47. Bajusz S, E. Szell, D. Bagdy, E. Barabas, G. Horvath, M. Dioszegi, Z. Fittler, G. Szabo, A. Juhasz, E. Tomori & et al: Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a tree tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J Med Chem 33, 1729-1735 (1990)
48. Chen LY, W. W. Nichols, C. Mattsson, A. C. Teger-Nilson, R. Wallin, T. G. Saldeen & J. L. Mehta: Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis. Cardiovasc Res 30, 866-874 (1995)
49. Teger-Nilsson AC, R. Bylund, D. Gustafsson, E. Gyzander & U. Eriksson: In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor. Thromb Res 85, 133-145 (1997)
50. Andersen K & M. Dellborg: Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group. Am J Cardiol 81, 939-944 (1998)
51. Swaan PW & J. J. Tukker: Molecular determinants of recognition for the intestinal peptide carrier. J Pharm Sci 86, 596-602 (1997)
52. Mehta JL, L. Chen, W. W. Nichols, C. Mattsson, D. Gustafsson & T. G. Saldeen: Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol 31, 345-351 (1998)
53. Das J, S.D. Kimball, S.E. Hall, W.C. Han, E. Iwanowicz, J. Lin, R.V. Moquin, I.A. Reid, J.S. Sack, M.F. Malley, C.Y. Chang, S. Chong, D.B. Wang-Iverson, D.G. Roberts, S.M. Seiler, W.A. Schumacher & M.L. Ogletree: Molecular design and structure-activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664. Bioorg Med Chem Lett 12, 45-49 (2002)
54. Bagdy D, E. Barabas, Z. Fittler, E. Orban, G. Rabloczky, S. Bajusz & E. Szell: Experimental oral anticoagulation by a directly acting thrombin inhibitor (RGH-2958) Folia Haematol Int Mag Klin Morphol Blutforsch 115, 136-140 (1988)
55. Mitchell TJ, R. M. Knabb, D. D. Christ, A. R. Farmer & T. M. Reilly: Analysis of the thrombin inhibitor DuP 714 by an enzyme-linked immunosorbent assay. Blood Coagul Fibrinolysis 5, 517-521 (1994)
56. Friederich PW, T. T. Keller, B. J. Biemond, R. J. Peters, W. Hornberger, H. R. Buller & M. Levi: Successful attenuation of venous thrombus growth in rabbits after the administration of a novel oral thrombin inhibitor. Thromb Haemost 84, 858-864 (2000)
57. McClanahan TB, G. W. Hicks, D. P. Ignasiak, R. Bousley, T. E. Mertz, P. Juneau, N. Janiczek-Dolphin, I. C. Kim & K. P. Gallagher: The Antithrombotic Effects of CI-1028, an Orally Bioavailable Direct Thrombin Inhibitor, in a Canine Model of Venous and Arterial Thrombosis. J Thromb Thrombolysis 10, 277-284 (2000)
58. Dominguez C, D.E. Duffy, Q. Han, R.S. Alexander, R.A. Galemmo Jr, J.M. Park, P.C. Wong, E.C. Amparo, R.M. Knabb, J. Luettgen, R.R. Wexler: Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors. Bioorg Med Chem Lett 9, 925-930 (1999)
59. Cook JJ, S. J. Gardell, M. A. Holahan, G. R. Sitko, G. L. Stump, A. A. Wallace, D. B. Gilberto, T. R. Hare, J. A. Krueger, D. L. Dyer, P. E. Sanderson, J. P. Vacca, J. A. Shafer & J. J. Lynch Jr: Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis. J Pharmacol Exp Ther 289, 503-510 (1999)
60. Bock LC, L. C. Griffin, J. A. Latham, E. H. Vermaas & J. J. Toole: Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355, 564-566 (1992)
61. Latham JA, R. Johnson, & J. J. Toole: The application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing 5-(1-pentynyl)-2′-deoxyuridine. Nucleic Acids Res 22, 2817-2822 (1994)
62. Li WA, A. V. Kaplan, G. W. Grant, J. J. Toole & L. L. Leung: A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. Blood 83, 677-682 (1994)
63. Eriksson BI, S. Ekman, P. Kalebo, B. Zachrisson, D. Bach & P. Close: Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 347, 635-639 (1996)
64. Ginsberg JS, M. T. Nurmohamed, M. Gent, B. MacKinnon, J. Sicurella, P. Brill-Edwards, M. N. Levine, A. A. Panju, P. Powers, P. Stevens & et al. Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 90, 2385-2389 (1994)
65. Kleiman NS, C. B. Granger, H. D. White, P. Armstrong, D. Ardissino, F. V. de Werf, P. Zoldeyhi, T. D. Thompson, R. M. Califf & E. J. Topol: Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. Am Heart J 137, 12-23 (1999)
66. Pina I: FDA panel votes against approval for bivalirudin. Circulation 99, 1277 (1999)
67. The Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344, 1383-1389 (1994)
68. Sacks FM, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, L. Brown, J.W. Warnica, J.M. Arnold, C.C. Wun, B.R. Davis & E. Braunwald: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335, 1001-1009 (1996)
69. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339, 1349-1357 (1998)
70. Collins R, R. Peto, J. Armitage: The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract 56, 53-56 (2002)
71. Collins R, J. Armitage, S. Parish, P. Sleigh, R. Peto: Heart Protection study Collaborative Group:MRC/BHF Heart Protection Study of cholesterol-lowering with Simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361, 2005-2016 (2003)
72. Shen GX: Statins: Effects beyond cholesterol lowering. Guest Editor's comments. Cur Drug Target: Cardiovasc Haematol Disord 5:111-113 (2005)
73. Ferro D, S. Basili, C. Alessandri, B. Mantovani, C. Cordova, F. Violi: Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia. Lancet 350, 1222 (1997)
74. Fenton II JW & G.X. Shen: Statins as cellular antithrombotics. Haemostasis 29, 166-169 (1999)
75. Ludwig S, S. Dharmalingam, S. Erickson-Nesmith, S. Ren, F. Zhu, G. M. Ma, R. Zhao, J. W. Fenton II, F. A. Ofosu, H. te Velthuis, G. van Mierlo & G. X. Shen: Impact of Simvastatin on hemostatic and fibrinolytic regulators in type 2 diabetic mellitus. Diabetes Res Clin Prac Epub. April 29 (2005)
76. Davignon J & L. Mabile: Mechanisms of action of statins and their pleiotropic effects. Ann Endocrinol 62, 101-112 (2001)
77. Eto M, T. Kozai, F. Cosentino, H. Joch & T.F. Luscher: Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105, 1756-1759 (2002)
78. Moghadasian MH: A safety look at currently available statins. Expert Opin Drug Saf 1, 269-274 (2002)